|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | MorphoSys AG (Frankfurt Stock Exchange MOR), a developer of technology aiding in the production of synthetic antibodies. |
|---|---|
| Transferring Party | Biogenesis Ltd. (U.K.) and Biogenesis Inc. (U.S.), manufacturers of antibodies for the life science research community. |
| Sector | Biopharmaceuticals |
| Date | January 20, 2005 |
| Analysis Establishes MorphoSys as one of the top five European suppliers of antibodies, as well as providing it access to new antibody technology. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |